Description

Composition:

Each tablet contains:
solifenacin succinate 6 mg
tamsulosin hydrochloride 0.4 mg

Auxiliary components:
Hypromelose, carboner, microcrystalline cellulose, colodial silicone dioxide, magnesium stearate, lactose monohydrate.

Properties:

Combined drug containing two active substances, solifenacin and tamsulosin. These active substances have independent and complementary mechanisms of action in the treatment of symptoms of lower urinary tract diseases associated with benign prostatic hyperplasia, in the presence of symptoms of filling.
Solifenacin is a selective competitive inhibitor of bladder muscarinic receptors, mainly of t M3 subtype, has low or no affinity for other receptors, enzymes and ion channels.

Tamsulosin is an alpha-I blocker. It is a selective competitive blocker of postsynaptic al-adrenergic receptors, especially alA and alD subtypes, which are responsible for relaxing the smooth muscles of the lower urinary tract.

Indications:

Treatment of moderate to severe filling symptoms (irritative symptoms) (urge to urinate, urinary frequency) and emptying symptoms (obstructive symptoms) associated with benign prostatic hyperplasia in men.

Method of administration and dosage:

The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

On average, one tablet is taken per day.

The maximum dose per day is 1 (6mg / 0.4mg) Tamsulin Plus tablet.